1. Chimerism New Products

2. Extension of marker set
Addition of 10 markers

3. Extension of marker set
With corresponding new IFU
Information included on added markers
Figure on marker locations
Additional information on:
Fluorophores and channels for KMRtype multiplex
Data analysis with qPCR and KMRengine

4. Pre-transplant sample
Needed for monitoring
Limited over time
Replacement with previous post-transplant sample
Experiments with reagents have been performed
Software needs to be adjusted
 future development

5. HLA markers
Early access program

6. Delicate HLA balance Matched HLA Mismatched HLA
To prevent Graft-versus-Host disease
Mismatched HLA
For Graft-versus-Leukemia effect
Residual disease
Control residual disease. Important to know more about HLA expression at time of relapse.
Removal of T cells in favour of one and not in favour of the other.

7. Delicate HLA balance Cancer cells evade immune system
Down regulation of HLA
No mismatched HLA for current donor
HLA status at time of relapse for treatment
Control residual disease. Important to know more about HLA expression at time of relapse.
Removal of T cells in favour of one and not in favour of the other.

8. Current marker set Bi-allelic variants Well described and published
Insertions/deletions
SNPs
Well described and published
No HLA markers yet. Tricky area.

9. Collaboration
We do not work alone. We work with the experts in the field. Collaboration with Essen and Milano.

10. HLA locus selection Haploidentical family donors Recipient DonorB C DR DQ DP
Matched unrelated donors (10/10)
Recipient
Donor A B C DR DQ DP
Which loci are taken into account during development.

11. Practical example
Example that HLA markers work in practise

12. In conclusion
Monitoring HLA loss at time of relapse is important for treatment strategy
HLA markers in addition to KMR markers
A product in development
Collaboration with Essen and Milano.

13. Other updates Further extension and integration of markers
CE-IVD registration
Your ideas?